PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Drug Interaction Between Ritonavir And Sitaxsentan
Phase 1
Withdrawn
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01251848
Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan
Phase 1
Withdrawn
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01251835
A Study In Japanese Healthy Male Volunteers To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-02341066
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2011-11-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT01250730
- Locations
- 🇯🇵
Pfizer Investigational Site, Hachioji-shi, Tokyo, Japan
A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
Phase 4
Completed
- Conditions
- Healthy Subjects
- Interventions
- Biological: 7-pneumococcal conjugate vaccine (7vPnC)Biological: DTaPBiological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2013-02-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 321
- Registration Number
- NCT01250756
- Locations
- 🇯🇵
Yamashita Pediatrics Clinic, Itoshima, Fukuoka, Japan
🇯🇵Shibuya Clinic, Kumagaya-city, Saitama, Japan
🇯🇵Matsuyama Red Cross Hospital, Matsuyama-city, Ehime, Japan
Single Dose Escalation Study of PF-05190457 in Healthy Volunteers
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2011-07-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT01247896
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Comparison Of A Single PF-04634817 Tablet Dose Compared With A Solution In Healthy Volunteers
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT01247883
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
CP-690-550 Ointment For Chronic Plaque Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: Vehicle 1Drug: CP-690,550 Ointment 1Drug: CP-690,550 Ointment 2Drug: Vehicle 2
- First Posted Date
- 2010-11-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT01246583
- Locations
- 🇺🇸
Horizon Research Group, Inc., Mobile, Alabama, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Expresscare Medical, Los Angeles, California, United States
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
Completed
- Conditions
- Macular DegenerationAge-related Macular DegenerationNeovascular Macular Degeneration
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1001
- Registration Number
- NCT01245387
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Phase 1
Terminated
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT01244620
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Effects Of PF-02545920 On Ketamine-Induced Abnormal Prefrontal Brain Response To Associative Learning In Healthy Subjects
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2014-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT01244880
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States